Insider Buying: X4 Pharmaceuticals (NASDAQ:XFOR) Chairman Acquires $11,868.00 in Stock

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Chairman Adam Craig acquired 4,600 shares of the firm’s stock in a transaction on Friday, October 16th. The stock was purchased at an average price of $2.58 per share, with a total value of $11,868.00. Following the acquisition, the chairman owned 333,251 shares of the company’s stock, valued at $859,787.58. This represents a 1.40% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

X4 Pharmaceuticals Stock Performance

Shares of XFOR stock opened at $3.01 on Thursday. X4 Pharmaceuticals, Inc. has a 12 month low of $2.43 and a 12 month high of $4.83. The company has a debt-to-equity ratio of 0.49, a quick ratio of 11.02 and a current ratio of 11.30. The company’s fifty day moving average price is $3.45 and its 200-day moving average price is $3.86.

X4 Pharmaceuticals (NASDAQ:XFOR) last released its earnings results on Thursday, August 6th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.05. The firm had revenue of $8.81 million for the quarter, compared to the consensus estimate of $2.42 million. X4 Pharmaceuticals had a negative net margin of 568.80% and a negative return on equity of 63.05%. Equities analysts expect that X4 Pharmaceuticals, Inc. will post -0.67 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts recently commented on the stock. Weiss Ratings lowered shares of X4 Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday. Wells Fargo & Company initiated coverage on shares of X4 Pharmaceuticals in a research note on Friday, July 10th. They set an “overweight” rating and a $11.00 target price for the company. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $11.25.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in XFOR. Perceptive Advisors LLC boosted its holdings in X4 Pharmaceuticals by 6.7% in the first quarter. Perceptive Advisors LLC now owns 6,737,648 shares of the company’s stock worth $27,826,000 after acquiring an additional 423,196 shares in the last quarter. Bank of New York Mellon Corp bought a new position in shares of X4 Pharmaceuticals during the second quarter valued at $917,000. Bank of America Corp DE increased its holdings in shares of X4 Pharmaceuticals by 321.3% during the first quarter. Bank of America Corp DE now owns 150,676 shares of the company’s stock valued at $622,000 after acquiring an additional 114,915 shares in the last quarter. Squarepoint Ops LLC bought a new position in shares of X4 Pharmaceuticals during the second quarter valued at $313,000. Finally, Wellington Management Group LLP purchased a new position in shares of X4 Pharmaceuticals in the 2nd quarter worth about $242,000. Hedge funds and other institutional investors own 72.03% of the company’s stock.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases caused by immune and hematologic dysfunction. The company’s research centers on the CXCR4 biological pathway, which regulates the movement and retention of certain immune cells in the bone marrow and other tissues.

X4’s primary product is XOLREMDI (mavorixafor), an oral CXCR4 antagonist approved by the U.S. Food and Drug Administration in 2024 for use in people aged 12 and older with WHIM syndrome.